FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2005451608> ?p ?o ?g. }

• W2005451608 endingPage "184" @default.
• W2005451608 startingPage "179" @default.
• W2005451608 abstract "BackgroundData comparing the incidence and pattern of interstitial lung disease (ILD) in non-small cell lung cancer patients receiving treatment with gefitinib versus erlotinib, both of which are epidermal growth factor receptor tyrosine kinase inhibitors, are scarce. We investigated the incidence of ILD in Japanese patients treated with gefitinib or erlotinib.MethodsWe reviewed the clinical records of 209 patients treated with erlotinib in 2008 (cohort A) and 330 treated with gefitinib between 2000 and 2003 (cohort B). Toxicity within the first month of treatment was investigated.ResultsThe patients in cohort A had fewer known risk factors for ILD (e.g., poor performance status and prior pulmonary fibrosis). ILD was detected in two patients (1.0%) from cohort A and eight patients (2.4%) from cohort B during the first month of treatment. The events were graded as follows: one patient each in grades 1 and 2 (cohort A), and one, one, and six patients in grades 3, 4, and 5, respectively (cohort B). Multivariate analysis revealed that poor performance status and prior pulmonary fibrosis were significantly correlated with the occurrence of ILD, but the type of epidermal growth factor receptor tyrosine kinase inhibitor administered was not.ConclusionThere was a somewhat lower incidence of ILD with erlotinib therapy than with gefitinib therapy, despite no statistically significant difference. Patient selection based on awareness by Japanese physicians of the risk factors for ILD, rather than the type of agent, may explain the difference in ILD incidence between the two treatments. Data comparing the incidence and pattern of interstitial lung disease (ILD) in non-small cell lung cancer patients receiving treatment with gefitinib versus erlotinib, both of which are epidermal growth factor receptor tyrosine kinase inhibitors, are scarce. We investigated the incidence of ILD in Japanese patients treated with gefitinib or erlotinib. We reviewed the clinical records of 209 patients treated with erlotinib in 2008 (cohort A) and 330 treated with gefitinib between 2000 and 2003 (cohort B). Toxicity within the first month of treatment was investigated. The patients in cohort A had fewer known risk factors for ILD (e.g., poor performance status and prior pulmonary fibrosis). ILD was detected in two patients (1.0%) from cohort A and eight patients (2.4%) from cohort B during the first month of treatment. The events were graded as follows: one patient each in grades 1 and 2 (cohort A), and one, one, and six patients in grades 3, 4, and 5, respectively (cohort B). Multivariate analysis revealed that poor performance status and prior pulmonary fibrosis were significantly correlated with the occurrence of ILD, but the type of epidermal growth factor receptor tyrosine kinase inhibitor administered was not. There was a somewhat lower incidence of ILD with erlotinib therapy than with gefitinib therapy, despite no statistically significant difference. Patient selection based on awareness by Japanese physicians of the risk factors for ILD, rather than the type of agent, may explain the difference in ILD incidence between the two treatments." @default.
• W2005451608 created "2016-06-24" @default.
• W2005451608 creator A5000588868 @default.
• W2005451608 creator A5001897650 @default.
• W2005451608 creator A5005471303 @default.
• W2005451608 creator A5006348007 @default.
• W2005451608 creator A5007888883 @default.
• W2005451608 creator A5012233359 @default.
• W2005451608 creator A5023876173 @default.
• W2005451608 creator A5025249611 @default.
• W2005451608 creator A5025271372 @default.
• W2005451608 creator A5027732689 @default.
• W2005451608 creator A5029433650 @default.
• W2005451608 creator A5032616275 @default.
• W2005451608 creator A5034733511 @default.
• W2005451608 creator A5039723911 @default.
• W2005451608 creator A5052246946 @default.
• W2005451608 creator A5052312623 @default.
• W2005451608 creator A5062920555 @default.
• W2005451608 creator A5066700160 @default.
• W2005451608 creator A5070015883 @default.
• W2005451608 creator A5075169533 @default.
• W2005451608 date "2010-02-01" @default.
• W2005451608 modified "2023-10-01" @default.
• W2005451608 title "Comparison of the Incidence and Pattern of Interstitial Lung Disease During Erlotinib and Gefitinib Treatment in Japanese Patients with Non-small Cell Lung Cancer: The Okayama Lung Cancer Study Group Experience" @default.
• W2005451608 cites W1913616561 @default.
• W2005451608 cites W1995119153 @default.
• W2005451608 cites W2012773370 @default.
• W2005451608 cites W2031248807 @default.
• W2005451608 cites W2049484790 @default.
• W2005451608 cites W2107943787 @default.
• W2005451608 cites W2122553809 @default.
• W2005451608 cites W2122712858 @default.
• W2005451608 cites W2129404873 @default.
• W2005451608 cites W2135836172 @default.
• W2005451608 cites W2138297714 @default.
• W2005451608 cites W2145238269 @default.
• W2005451608 cites W2149095868 @default.
• W2005451608 cites W2165803850 @default.
• W2005451608 cites W2235706971 @default.
• W2005451608 cites W2416914730 @default.
• W2005451608 cites W2104494428 @default.
• W2005451608 doi "https://doi.org/10.1097/jto.0b013e3181ca12e0" @default.
• W2005451608 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20101144" @default.
• W2005451608 hasPublicationYear "2010" @default.
• W2005451608 type Work @default.
• W2005451608 sameAs 2005451608 @default.
• W2005451608 citedByCount "63" @default.
• W2005451608 countsByYear W20054516082012 @default.
• W2005451608 countsByYear W20054516082013 @default.
• W2005451608 countsByYear W20054516082014 @default.
• W2005451608 countsByYear W20054516082015 @default.
• W2005451608 countsByYear W20054516082016 @default.
• W2005451608 countsByYear W20054516082017 @default.
• W2005451608 countsByYear W20054516082018 @default.
• W2005451608 countsByYear W20054516082019 @default.
• W2005451608 countsByYear W20054516082020 @default.
• W2005451608 countsByYear W20054516082021 @default.
• W2005451608 countsByYear W20054516082022 @default.
• W2005451608 countsByYear W20054516082023 @default.
• W2005451608 crossrefType "journal-article" @default.
• W2005451608 hasAuthorship W2005451608A5000588868 @default.
• W2005451608 hasAuthorship W2005451608A5001897650 @default.
• W2005451608 hasAuthorship W2005451608A5005471303 @default.
• W2005451608 hasAuthorship W2005451608A5006348007 @default.
• W2005451608 hasAuthorship W2005451608A5007888883 @default.
• W2005451608 hasAuthorship W2005451608A5012233359 @default.
• W2005451608 hasAuthorship W2005451608A5023876173 @default.
• W2005451608 hasAuthorship W2005451608A5025249611 @default.
• W2005451608 hasAuthorship W2005451608A5025271372 @default.
• W2005451608 hasAuthorship W2005451608A5027732689 @default.
• W2005451608 hasAuthorship W2005451608A5029433650 @default.
• W2005451608 hasAuthorship W2005451608A5032616275 @default.
• W2005451608 hasAuthorship W2005451608A5034733511 @default.
• W2005451608 hasAuthorship W2005451608A5039723911 @default.
• W2005451608 hasAuthorship W2005451608A5052246946 @default.
• W2005451608 hasAuthorship W2005451608A5052312623 @default.
• W2005451608 hasAuthorship W2005451608A5062920555 @default.
• W2005451608 hasAuthorship W2005451608A5066700160 @default.
• W2005451608 hasAuthorship W2005451608A5070015883 @default.
• W2005451608 hasAuthorship W2005451608A5075169533 @default.
• W2005451608 hasBestOaLocation W20054516081 @default.
• W2005451608 hasConcept C120665830 @default.
• W2005451608 hasConcept C121332964 @default.
• W2005451608 hasConcept C121608353 @default.
• W2005451608 hasConcept C126322002 @default.
• W2005451608 hasConcept C143998085 @default.
• W2005451608 hasConcept C2776256026 @default.
• W2005451608 hasConcept C2777543607 @default.
• W2005451608 hasConcept C2777714996 @default.
• W2005451608 hasConcept C2778087573 @default.
• W2005451608 hasConcept C2778820342 @default.
• W2005451608 hasConcept C2779438470 @default.
• W2005451608 hasConcept C2780580887 @default.
• W2005451608 hasConcept C2909325608 @default.
• W2005451608 hasConcept C61511704 @default.
• W2005451608 hasConcept C71924100 @default.
• W2005451608 hasConcept C72563966 @default.

• next